Pasithea Therapeutics Corp. (KTTA) carries a Roarable Rating of D (Sell) with 44/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.
Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer
20D Institutional Volume Accumulation (±12.5% realized swing band)
Altman Z-Score 3.80 (FORTRESS SAFE (>3.0)) • Piotroski F-Score 2/9
Disciplined Float (+0.72% YoY Shares) & executive Form 4 sales trim 15 pts from alignment
While KTTA currently carries a cautious 44/100 (D) rating due to Insider Conviction & Share Dilution (5/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.
Established market leader in Health Care with deep daily trading liquidity.
Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($0.49) and Max Pain ($0.39) forces dealer call-delta covering toward $2.16.
Forensic Repair Trigger: Halting share dilution (Disciplined Float (+0.72% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.
Pasithea Therapeutics Corp. (KTTA) dropped -5.95% to $0.37, trading at 5% of its 52-week range ($0.28 – $2.06). Stretched risk/reward at current multiples (-35% return on capital) under elevated 10-year interest-rate pressure.
Rebecca M. Brown, MD, and Kavita Sarin, MD, PhD, will join management to discuss unmet needs and the treatment landscape for NF1-associated cutaneous and plexiform neurofibromasMIAMI, Oct. 28, 2026 (GLOBE NEWSWIRE) -- Pa
-- Prolonged Stable Disease: PAS-004 achieved prolonged stable disease in a heavily pre-treated population, with four patients on PAS-004 for more than 300 days, including two who continue on once daily PAS-004 for over
Pasithea Therapeutics Corp. (NASDAQ:KTTA) ("Pasithea" or the "Company"), a clinical-stage biotechnology company developing PAS-004, a next-generation macrocyclic oral MEK inhibitor, today announced
Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).
vs. +6.0% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).
No active Ellis Vennor swing setup published on KTTA today. View full Setup Ledger →
No direct multi-tier Butterfly edges indexed yet for KTTA. Explore sector supply chains on /butterfly.
Across 1016 tracked Health Care securities in the Roarable RQD universe, Pasithea Therapeutics Corp. (KTTA) ranks #525 by composite RQD confidence (44/100, grade D) and #875 by equity capitalization ($12.3M). Within this direct 5-issuer industry benchmark cohort, KTTA leads on earnings valuation at N/A trailing P/E, while KTTA leads on capital efficiency and profitability with -35.0% ROIC and — gross margin. KTTA currently leads its immediate peer cohort in composite quantitative strength at 44/100 (D).
| Ticker / Company | Roarable Grade | RQD Score | Trailing P/E | Gross Margin | ROIC | 1D Change | Market Cap | Head-to-Head |
|---|---|---|---|---|---|---|---|---|
| KTTA
ACTIVE
Pasithea Therapeutics Corp. | D | 44/100 | — | — | -35.0% | -5.95% | $12.3M | Benchmark Subject |
| HIND Vyome Holdings Inc. | D- | 35/100 | — | 68.4% | -35.0% | +1.74% | $12.3M | /hind-vs-ktta → |
| BOLT Bolt Biotherapeutics Inc. | E | 28/100 | — | — | -35.0% | -3.34% | $12.3M | /bolt-vs-ktta → |
| LPCN Lipocine Inc. | D- | 37/100 | — | — | -35.0% | +0.66% | $12.5M | /lpcn-vs-ktta → |
| BIVI BioVie Inc. (Class A) | E | 33/100 | — | — | -35.0% | -5.48% | $12.0M | /bivi-vs-ktta → |
In its most recent audited fiscal period (FY2025, filed 2025-12-31), Pasithea Therapeutics Corp. (KTTA) reported GAAP revenue of $0 (N/A vs. FY2024 revenue of $0 ) , GAAP net income of -$20.4M, operating cash flow of -$15.2M, and free cash flow of -$15.2M (-9.3% YoY). On the balance sheet, KTTA closed FY2025 with $60.2M in total assets against $0 in total debt (Altman Z-Score: N/A, Piotroski F-Score: 2/9).
| Fiscal Period | Filing Date | Revenue | Net Income | Operating Cash Flow | Free Cash Flow | Total Assets | Total Debt |
|---|---|---|---|---|---|---|---|
| FY2025 (FY) | 2025-12-31 | $0 | -$20.4M | -$15.2M | -$15.2M | $60.2M | — |
| FY2024 (FY) | 2024-12-31 | $0 | -$13.9M | -$13.9M | -$13.9M | $16.1M | — |
| FY2023 (FY) | 2023-12-31 | $0 | -$16.0M | — | — | — | — |
As of 2026-11-01, Pasithea Therapeutics Corp. (NASDAQ: KTTA) is rated D (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 44/100 at a spot price of $0.37 (-5.95% 1D, market cap $12.3M). Pillar breakdown: Fundamental Cash Engine 8/20, Institutional 13F & Options Flow 11/20, Executive Insider Alignment 10/20, FRED Macro Regime Fit 10/20, and SEC Balance-Sheet Forensics 5/20. Across 1016 tracked Health Care issuers, KTTA ranks #525 in composite RQD confidence.
Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), KTTA carries a Roarable D (44/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -35.0%. By comparison, HIND (Vyome Holdings Inc.) holds a D- grade (35/100 RQD, P/E N/A, ROIC -35.0%, cap $12.3M) and BOLT (Bolt Biotherapeutics Inc.) posts a E grade (28/100 RQD, P/E N/A, ROIC -35.0%, cap $12.3M). Among the 5-stock peer group, KTTA leads on earnings multiple (N/A) while KTTA leads on capital efficiency (-35.0% ROIC).
Per KTTA's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001841330), Pasithea Therapeutics Corp. generated $0 in revenue, -$20.4M in net income, and -$15.2M in free cash flow against $60.2M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.
KTTA last traded at $0.37 (-5.95% on volume of 329,816 shares), positioning the stock -24.49% below its 50-day simple moving average ($0.49) and -41.27% below its 200-day simple moving average ($0.63). Across its 52-week range of $0.28 to $2.06, KTTA sits at the 5.1% percentile with a 14-day RSI of 34.1 (NEUTRAL RANGE) and an implied next-earnings move of ±12.5% ($1.00 to $0.42).
Why KTTA Stock dropped -5.95% Today — RQD Quant Desk Flash. Stretched risk/reward at current multiples (-35% return on capital) under elevated 10-year interest-rate pressure.
To protect compute speed and zero-delay Cboe BZX data quality for active members, our current $9.95/month Roarable Pro cohort is 100% full. Join the priority waiting list below and we will notify you the moment the next batch of Pro accounts opens (and lock in your $9.95/mo rate).
Link your personal ChatGPT, Claude Desktop, or Cursor via Roarable's Model Context Protocol (`mcp.roarable.com`) to query all 5,289 stocks, inspect Butterfly supply chains, and trade your `$100K Arena` account.
Interrogate SEC 10-K/10-Q filings on demand and ask custom ticker, valuation, or short-thesis questions directly to any of our 8 specialized AI Quant Analysts.
Command our AI agents to sort and sift 5,289 stocks by custom formulas, follow multi-indicator technical & cash-flow setups, and send you instant Email/SMS breakout & downgrade alerts.
Unlock sub-second Cboe BZX streaming quotes, pre-market/after-hours delta scanners, instant SEC Form 4 insider cluster alerts, and unlimited portfolio stress-testing.
All 8 Roarable Analysts (Mara Quenwick, Devon Kess, Gideon Vane, Eliott Vance, Sorel Thorne, Corin Hale, Tessa Rane, and Felix Orven) are proprietary AI Quant Analysts and automated algorithmic specialists — not human financial advisors, fiduciaries, or registered broker-dealers. While one-to-many daily stock ratings and briefings are free, custom 1-on-1 Q&A, custom AI sifting/indicator alert agents, and personal ChatGPT/Claude MCP connections consume dedicated per-user compute and require a $9.95/month Roarable Pro membership. All AI outputs are for educational and research purposes only and never constitute individualized investment advice.
Enter your Google email below for instant 1-step account activation, daily A–E stock rating alerts, and immediate access to your $100,000.00 Paper Trading Arena account.